

Bayer AG Investor News 2001

December 07, 2001	Vardenafil: Up to 85 Percent of Men Achieved Significantly Improved Erections
December 06, 2001	Bayer to establish management holding company with operating subsidiaries
December 04, 2001	Bayer Receives FDA Approval for the Intravenous Form of Its Antibiotic Avelox® (moxifloxacin HCl)
November 15, 2001	Worldwide co-promotion agreement for vardenafil to treat erectile dysfunction
November 14, 2001	Earnings hampered by weak global economy and problems with Pharmaceuticals
November 06, 2001	Number of Bayer stockholders has risen by 100,000
October 02, 2001	Bayer acquires Aventis Crop Science
September 25, 2001	Bayer files applications for Vardenafil in United States and Mexico
September 13, 2001	Bayer plans to form separate companies for Health Care and Crop Protection
September 13, 2001	Werner Wenning will be new Bayer CEO
August 23, 2001	Bayer withdraws cholesterol-lowering drug in Japan too
August 17, 2001	Facts prove that Bayer gave authorities proper notification
August 17, 2001	Bayer says claims are without foundation
August 16, 2001	Bayer postpones listing on Wall Street
August 09, 2001	Sales increase, but earnings down
August 08, 2001	Bayer withdraws cholesterol-lowering drug Baycol/Lipobay
July 16, 2001	Bayer included in ethics indices
July 10, 2001	Bayer aims to acquire Aventis CropScience
June 27, 2001	Earnings forecast revised in the face of economic downturn
June 12, 2001	Bayer's pharmaceutical research strategy pays off: more than 40 substances in the pipeline
May 22, 2001	Epidaurus signs contract with Bayer
April 27, 2001	Sales up 10 percent in the first quarter of 2001
April 24, 2001	Bayer is looking for partners for its manmade fibers business
April 09, 2001	XVIth Congress of the European Association of Urology (EAU): New compound proves to be effective regardless of severity of erectile function difficulties, cause or age
April 09, 2001	Bayer subsidiary Wolff Walsrode to divest Covexx Films business to Wipak of Finland
March 15, 2001	Significant improvement in Health Care earnings
March 15, 2001	Bayer divests its remaining 30% stake in Agfa-Gevaert N.V.
March 06, 2001	Bayer increases dividend to EUR 1.40
February 01, 2001	Bayer acquires a leading maize herbicide in Europe
January 16, 2001	Bayer and CuraGen Enter into two Landmark Agreements
January 10, 2001	Bayer and Millennium announce genome-derived oncology drug candidate selected for first human studies
January 10, 2001	Bayer sells its interest in titanium dioxide joint venture

The news contents can be obtained from our website www.investor.bayer.com